Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: A nationwide register-based cohort study in denmark

CNS Drugs

Volumn 28, Issue 10, 2014, Pages 963-973

  Pasternak, Björn ^a   Svanström, Henrik ^a   Ranthe, Mattis F ^a   Melbye, Mads ^a,b   Hviid, Anders ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPARATIVE STUDY; DENMARK; FEMALE; FOLLOW UP; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CARDIOVASCULAR DISEASES; COHORT STUDIES; DENMARK; DIBENZOTHIAZEPINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK; RISPERIDONE; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84933053542     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0176-0     Document Type: Article

References (29)

1. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20:177-84.
2. Ilyas S, Moncrieff J. Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010. Br J Psychiatry. 2012;200:393-8.
3. Statens Serum Institut. Use of antipsychotics 2002-2011 [In Danish]; 2012.
4. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-43.
5. Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146:775-86.
6. Kales HC, Valenstein M, Kim HM, McCarthy JF, Ganoczy D, Cunningham F, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry. 2007;164:1568-76.
7. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359-69.
8. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227.
9. Pariente A, Fourrier-Reglat A, Ducruet T, Farrington P, Beland SG, Dartigues JF, et al. Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med. 2012;172:648-53.
10. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012;344:e977.
11. Huybrechts KF, Schneeweiss S, Gerhard T, Olfson M, Avorn J, Levin R, et al. Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc. 2012;60:420-9.
12. Brauer R, Douglas I, Smeeth L. The association between antipsychotic agents and the risk of myocardial infarction: a systematic review. Br J Clin Pharmacol. 2011;72:871-8.
13. Thomas SH, Drici MD, Hall GC, Crocq MA, Everitt B, Lader MH, et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand. 2010;122:345-55.
14. Pedersen CB. The Danish civil registration system. Scand J Public Health. 2011;39:22-5.
15. Kildemoes HW, Sorensen HT, Hallas J. The Danish National prescription registry. Scand J Public Health. 2011;39:38-41.
16. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663-7.
17. Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health. 2011;39:30-3.
18. Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health. 2011;39:26-9.
19. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol. 2003;56:124-30.
20. Johnsen SP, Overvad K, Sorensen HT, Tjonneland A, Husted SE. Predictive value of stroke and transient ischemic attack discharge diagnoses in the Danish national registry of patients. J Clin Epidemiol. 2002;55:602-7.
21. Tadrous M, Gagne JJ, Sturmer T, Cadarette SM. Disease risk score as a confounder summary method: systematic review and recommendations. Pharmacoepidemiol Drug Saf. 2013;22:122-9.
22. Sturmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol. 2005;161:891-8.
23. Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012;25:83-8.
24. Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry. 2011;168:193-201.
25. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225-35.
26. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374:620-7.
27. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-23.
28. Kreyenbuhl J, Slade EP, Medoff DR, Brown CH, Ehrenreich B, Afful J, et al. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia. Schizophr Res. 2011;131:127-32.
29. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8:114-26.